Unexpectedly high AUC levels in a child who received intravenous busulfan before stem cell transplantation

Bone Marrow Transplantation

Volumn 45, Issue 3, 2010, Pages 602-604

  Nishikawa, T ^a   Okamoto, Y ^a   Tanabe, T ^a   Shinkoda, Y ^a   Kodama, Y ^a   Higashi, M ^a   Hirano, H ^a   Arita, K ^a   Kawano, Y ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CISPLATIN; COTRIMOXAZOLE; ETOPOSIDE; GANCICLOVIR; IFOSFAMIDE; MELPHALAN; METHYLPREDNISOLONE; THIOTEPA;

AREA UNDER THE CURVE; ARTIFICIAL VENTILATION; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER RECURRENCE; CASE REPORT; CHILD; CRANIOTOMY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MEGADOSE; DYSPNEA; ENGRAFTMENT; HUMAN; HUMAN TISSUE; LETTER; LUNG TOXICITY; MALE; MEDULLOBLASTOMA; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY FAILURE;

AREA UNDER CURVE; BUSULFAN; CEREBELLAR NEOPLASMS; CHILD; DRUG MONITORING; FATAL OUTCOME; GLUTATHIONE TRANSFERASE; HUMANS; INJECTIONS, INTRAVENOUS; LUNG; MALE; MEDULLOBLASTOMA; MYELOABLATIVE AGONISTS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 77949425415     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.195     Document Type: Letter

References (10)

1. Myers JL, El-Zammar O. Pathology of drug-induced lung disease. In: Katzenstein AL (ed). Katzenstein and Askin's Surgical Pathology of Non-Neoplastic Lung Disease, 4th edn. Elsevier Publishing Ltd: Philadelphia, PA, 2006, pp 85-89.
2. Kalaycio M, Pohlman B, Kuczkowski E, Rybicki L, Andresen S, Sobecks R et al. High-dose busulfan and the risk of pulmonary mortality after autologous stem cell transplant. Clin Transplant 2006; 20: 783-787.
3. Henner WD, Furlong EA, Flaherty MD, Shea TC, Peters WP et al. Measurement of busulfan in plasma by high-performance liquid chromatography. J Chromatogr 1987; 416: 426-432.
4. Li CK, Yuen PM, Wong R, Pang CP, Lai WK, Chik KW et al. Busulphan level and early mortality in thalassaemia patients after BMT. Bone Marrow Transplant 1999; 23: 307-310.
5. Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17: 225-230.
6. Czerwinksi M, Gibbs JP, Slattery JT. Busulfan conjugation by glutathione S-transferases alpha, mu and pi. Drug Metab Dispos 1996; 24: 1015-1019.
7. Johnson L, Orchard PJ, Baker KS, Brundage R, Cao Q, Wang X et al. Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation. J Clin Pharmacol 2008; 48: 1052-1062.
8. Nguyen L, Leger F, Lennon S, Puozzo C. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. Cancer Chemother Pharmacol 2006; 57: 191-198.
9. Vassal G, Michel G, Esperou H, Gentet JC, Valteau-Couanet D, Doz F et al. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol 2008; 61: 113-123.
10. Stein J, Davidovitz M, Yaniv I, Ben-Ari J, Gamzu Z, Hoffer E et al. Accidental busulfan overdose: enhanced drug clearance with hemodialysis in a child with Wiskott-Aldrich syndrome. Bone Marrow Transplant 2001; 27: 551-553.